What Has Been the Growth of the Curosurf Poractant Alfa Market So Far?
The curosurf poractant alfa market has seen considerable growth due to a variety of factors.
• In recent times, the market size for curosurf (poractant alfa) has seen an HCAGR of XX. It is projected to rise from $XX million in 2024 to $XX million in 2025, signifying a compound annual growth rate (CAGR) of XX%.
This growth over the historic period is attributable to a rise in demand for advanced medical technologies, the utilization of synthetic surfactants in sanitary products, greater healthcare awareness, improved healthcare access, and preference for greater ease of cleanliness. Consequently, these factors have led to an increase in sales of synthetic surfactant and escalated health awareness.
How Will the Curosurf Poractant Alfa Market Size In The Coming Years?
The curosurf poractant alfa market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of curosurf (poractant alfa) is projected to achieve XX (FCAGR) in the forthcoming years, eventually reaching $XX million in 2029 with an anticipated compound annual growth rate (CAGR) of XX%.
The predicted growth during this period can be ascribed to a rise in premature births, increased utilization of synthetic surfactants in agrochemicals, the escalating incidence of chronic respiratory disorders, an increase in healthcare spending, and a growing preference for treating respiratory infections. The major tendencies anticipated during this forecast period include the employment of microdosing strategies, the incorporation of surfactant therapy, the adoption of biologic and immunomodulatory therapies, a shift towards sustainable and green surfactants, and a heightened focus on neonatal and paediatric care.
What Main Forces Are Fueling Expansion In The Curosurf Poractant Alfa Market?
The rising prevalence of respiratory conditions is anticipated to accelerate the curosurf (poractant alfa) market growth. Such disorders commonly affect the lungs and obstruct normal breathing functions, examples include asthma, COPD, and lung cancer. Acute difficulties in breathing and diminished lung capacities are symptoms of these disorders. The increasing air pollution levels are exacerbating conditions like asthma, while the aging demographic contributes to a higher frequency of age-related diseases such as COPD. Poractant alfa is employed to cure neonatal respiratory distress syndrome by enhancing lung efficiency and aiding breathing in preterm infants through endotracheal tube administration. For example, the National Asthma Council, an Australian non-profit organization, reported 467 asthma-related fatalities in Australia in 2022, consisting of 299 women and 168 men, which is an increase from the 355 deaths of 2021. Hence, the curosurf (poractant alfa) market's growth is being driven by the escalating prevalence of such respiratory illnesses. Likewise, the increasing occurrence of premature births is projected to boost the Curosurf (poractant alfa) market's expansion. Premature births are when babies are delivered before the 37th week of gestation, given that a typical full-term pregnancy lasts about 40 weeks. The surge in premature births can be associated with advanced maternal age and a rise in the utilization of assisted reproductive technologies, which frequently result in multiple pregnancies. Poractant alfa functions by reducing lung surface tension in premature infants with respiratory distress syndrome, which assists in sustaining lung openness and enhances oxygen exchange. The Office for National Statistics, a UK-based government department, revealed in May 2024 that the premature live birth rate in England and Wales for 2022 was 7.9%, a growth from 7.5% in 2021. Consequently, the rapid proliferation of premature births is fuelling the growth of the Curosurf (poractant alfa) market.
What Key Areas Define The Segmentation Of The Global Curosurf Poractant Alfa Market?
The curosurf (poractant alfa) market covered in this report is segmented –
1) By Type: Natural Poractant Alfa, Synthetic Poractant Alfa
2) By Sales Channel: Direct Sales, Distribution Channels, Online Marketplace
3) By Application: Pulmonary Edema, Respiratory Distress Syndrome, Other Respiratory Disorders
4) By End User: Hospitals, Clinics, Ambulance Services
Pre-Book The Curosurf Poractant Alfa Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Curosurf Poractant Alfa Market?
The predominant trend in the Curosurf (poractant alfa) market is concentration on the creation of groundbreaking solutions, such as new inhalable gene therapeutics aimed at unmet needs in pulmonary conditions. This advanced strategy enables the direct delivery of therapeutic genes to the lungs via inhalation, using aerosolized particles or nanoparticles. For instance, in November 2024, AlveoGene, a gene therapy creator based in the UK, procured the Rare Pediatric Disease Designation (RPDD) from the FDA for AVG-002. This innovative inhaled gene therapy targets a deadly neonatal disorder called surfactant protein B (SP-B) deficiency, a serious genetic disease that triggers respiratory failure in infants. SP-B deficiency, which arises from mutations in the SFTPB gene, currently has sparse treatment alternatives, with lung transplant being the main option. AVG-002 deploys AlveoGene's InGenuity platform to deliver a functioning SP-B gene directly to the lungs and has demonstrated encouraging results in early studies.
Who Are the Key Players In The Curosurf Poractant Alfa Market?
Major companies operating in the curosurf (poractant alfa) market include:
• Chiesi Farmaceutici S.p.A
What Is The Most Dominant Region In The Curosurf Poractant Alfa Market?
North America was the largest region in the curosurf (poractant alfa) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
